

CURRICULUM VITAE

- I.
- (a) Name: Olayinka Adejoke Kotila (nee Odunsi)
 - (b) Date of birth: 3 August, 1975
 - (c) Department: Pharmaceutical Chemistry
 - (d) Faculty: Pharmacy
- II. University Education (with dates)
- (a) University of Ibadan, Ibadan 1993 - 1999
 - (b) University of Ibadan, Ibadan 2004 - 2006
 - (c) University of Ibadan, Ibadan 2013 - 2018
- III. Academic Qualifications (with dates and granting bodies)
- (a) Bachelor of Pharmacy (B. Pharm), University of Ibadan Feb., 1999
 - (b) Master of Science (Pharmaceutical Chemistry), University of Ibadan Nov., 2006
 - (c) Doctor of Philosophy (Pharmacokinetics and Bioavailability Studies), University of Ibadan June 2018
- IV. Professional Qualifications and Diplomas (with dates)
- a) Registered Pharmacist - Pharmaceutical Society of Nigeria (MPSN) Feb., 1999
 - b) Certificate of Participation, The Role of Pharmacogenetics in Drug Discovery, University of Ibadan, Nigeria Mar., 2015
 - c) Certificate of Completion, Overview of Supply Chain Management for Health Commodities. 15-19 Feb. 2016
 - d) Certificate of Completion, Ethics and Responsible Conduct of Research 27-28 June 2018
 - e) Certificate of Completion, Pharmacometrics Training Course in Physiologically-Based Pharmacokinetics (PBPk) Modelling and its Applications. 12-16 Nov., 2018
 - f) Certificate of Completion, Statistical Genetics 19-24 Jan., 2019
 - g) Certificates of Participation USP Self-Paced eLearning Jan. – Feb., 2021
Foundations of GMP: [Qualification, Active Pharmaceutical Ingredient (API), Auditing, Heating, Ventilation, and Air Conditioning (HVAC) Systems]
 - h) Certificate of Completion, CITI Conflicts of Interest 13 Jan., 2022
 - i) Certificate of Completion, USP Foundations of GMP: Deviations, Root Cause Analysis (RCA) Tools and Corrective and Preventive Action (CAPA) - Sequence flow for handling of any non-conformance in the GMP environment 6 June, 2022
 - j) Certificate of Participation, Oncology Pharmacy Jan. - April, 2023
 - k) Certificate of Participation, USP-PQM+ Good Manufacturing Practice Training on Quality Risk Management (QRM) Application 11-14 April, 2023
 - l) Certificate of Completion, CITI Program on Good Clinical Practice 19 Sept., 2023
 - m) Certificate of Participation, USP-PQM+ Common Technical Document Dossier Compilation 11-15 March, 2024
 - n) Certificate of Participation, USP-PQM+ Training on Good Practices for Pharmaceutical Quality Control Laboratories 20-24 May, 2024
 - o) Certificate of Participation, Animal Care and Use Research Ethics Committee (ACUREC) Workshop 25 June 2024
- V. Scholarships, Fellowships and Prizes (with dates)
- a) MacArthur Foundation Multidisciplinary Research Grant (Grant # 11-97968--000-INP) (Co-Investigator) October 2009
 - b) Global Health Initiative Fellowship Award, University of Chicago, USA 2010 & 2011

- | | | |
|----|--|------|
| c) | MEPIN Year 02 Seed Award (Award number R24TW008878 from the Fogarty International Center) | 2012 |
| d) | Wellcome Trust Bursary Award | 2012 |
| e) | Novartis Scholarship Award – Pharmacometrics Course in Tanzania | 2013 |
| f) | NIH D43 Re-entry Grant Award (1D43TW009112-01A1) | 2013 |
| g) | Tertiary Education Trust Fund (TETFund) - Academic Staff Training and Development Fund (AST&D) | 2014 |
| h) | Thomas-Bassir Biomedical Foundation Small Research Grants | 2017 |
| i) | Travel Grant to attend Fogarty International Centre (FIC) Global Network of Grant Holders and their Grantees Focused on Non-communicable Diseases (NCDs) | 2018 |
| j) | TETFUND Research Project Fund on “Pharmaceutical Quality of Selected Anticancer Drugs (Doxorubicin, Epirubicin and Cyclophosphamide) marketed in South West Nigeria (Co-Investigator) | 2019 |
| k) | United States Pharmacopeia (USP) Promoting Quality of Medicines Plus (PQM+) Program – a USAID Cooperative Agreement funded project. Centre for Drug Discovery, Development and Production is a CoreFlex partner with USP | 2019 |
| l) | University of Ibadan Research Foundation (Co-Investigator) | 2020 |
| m) | Tertiary Education Trust Fund (TETFund) Special Covid-19 Intervention Grant (TETFund/DR&D/CE/SI/COV-19/UI/Vol.1) (Co-Investigator) | 2020 |

VI. Honours, Distinctions and Membership of Learned Societies

- | | | |
|----|---|----------------|
| a. | Member, Pharmaceutical Society of Nigeria (MPSN) | 1999 till date |
| b. | Member, Nigerian Association of Pharmacists in Academia (NAPA) | 2008 till date |
| c. | Member, International Society for Study of Xenobiotics (ISSX) | 2012 |
| d. | Member, African Society of Human Genetists (AfSHG) | 2018 till date |
| e. | African Society of Human Genetics (AfSHG) and H3Africa Consortium Bursary Award (Won Best Oral Presentation at the conference) | 2018 |
| f. | Winter Institute in Statistical Genetics Grant Award | 2019 |
| g. | British Journal of Clinical Pharmacology’s (BJCP) 2022-2023 Africa Publication Workshop Competition Award (Pioneer Award Winner) | 2023 |

VII (a) Past Work Experience

- | | | |
|---|---|-------------|
| • | Internship – Had my internship training at the University College Hospital (UCH), Ibadan | 1999 - 2000 |
| • | Community Pharmacist – Worked as a Locum Pharmacist at CRAN Pharmacy and Stores, Challenge, Ibadan | 2000 - 2002 |
| • | Hospital Pharmacist (Grade I) – Worked with the Oyo State Hospitals Management Board (OYSHMB) as a Grade I Pharmacist | 2002 - 2008 |

(b) Administrative Experience at the University Level

- | | | |
|-------|---|----------------|
| i. | Rapporteur, UI @ 60 Exhibition | 2008 |
| ii. | Member, Induction committee | 2008 – 2014 |
| iii. | Member, Computer committee | 2010 - 2016 |
| iv. | Member, CDDDP Implementation committee | 2011 - 2017 |
| v. | Departmental Class Coordinator for 500 Level | 2012 till date |
| vi. | Member, Faculty Dress Code Committee | 2013 |
| vii. | Member, Faculty Alumni Executive Committee | 2013 till date |
| viii. | Member, UI/UCH Institutional Review Committee, UI, Nigeria. | 2014 - 2022 |
| ix. | Member, National Association of Pharmacist in Academia (NAPA) Executive Committee | 2014 - 2023 |
| x. | Coordinator, departmental Undergraduate program | 2017 - 2021 |
| xi. | Member, Faculty Curriculum Committee | 2017 |

xii.	Assistant Hall Warden, Queen Idia Hall (Largest female hall in the university)	2019 - 2023
xiii.	Staff Adviser, Queen Idia Hall	2019 - 2023
xiv.	Senate Member, University of Ibadan	2020 - 2022
xv.	Coordinator, departmental Postgraduate program	2023 -

VIII. Courses Taught Undergraduate Students

<u>Course code</u>	<u>Course Title</u>	<u>Units</u>	<u>Percentage teaching time (%)</u>
PCH 201	Inorganic & Physical Pharmaceutical Chemistry	3	13
PCH 301	Analytical Pharmaceutical Chemistry I	3	20
PCL 402	Chemistry of Drugs and Pharmacology of Nervous System		
PCL 403	Chemotherapy I		
PCH 501	Pharmaceutical Analysis II	3	27
PCH 504	Practical Pharmaceutical Chemistry IV		100

Courses Taught Postgraduate Students

PCH 701	Principles of Pharmacokinetics in Analytical Medicinal Chemistry	3	80
PCH 705	Bioanalytical and Biopharmaceutical Methods of Drug Analysis	4	50
PCH 710	Drug Metabolism and Toxicology	2	100
DDD 707	Basics of Clinical Trials and Bioethics in Drug Development	3	100

IX. Research
(a) Completed

- Analytical method development: I have been engaged in research works that focused on analytical method development for anti-infectives such as lumefantrine, co-trimoxazole, and artemisinin derivatives to mention a few.
- Analytical method development using high performance liquid chromatography (HPLC) for simultaneous analysis of 5-Fluorouracil, cyclophosphamide, and epirubicin (FEC) in serum is being carried out.
This research is part of the ARETTA study and will be effective in helping to quantify the concentrations of these drug in patients recruited into the study.
- Pharmacokinetics-Pharmacogenetics Studies: I have completed pharmacokinetic studies on dapson and investigated genotype-phenotype relationship associated with a drug metabolizing gene, N-acetyltransferase 2 and use of sulphonamides in Nigerians.
- Analytical method development

(b) In progress

- Pharmacokinetics-Pharmacogenetics Studies
 - Epidemiological genotyping of detoxifying genes (GSTT, GSTP, GSTM) and CYP2C9 drug metabolizing enzyme in Nigerians.

- Protocol development for genotype-phenotype correlation of plasma concentration of dolutegravir in HIV-positive Nigerian patients

These two ongoing research works are sequel to the completed genotyping of N-acetyltransferase 2. The goal is to gather genotype information related to adverse drug reactions in vulnerable Nigerians, such as HIV-positive individuals. Laboratory work and data analysis are more than 90% completed. It is expected that findings will guide dosing regimen in predisposed individuals.

- Clinical Studies on Female-associated Cancers
 - Assessing response to neoadjuvant taxotere and subcutaneous Trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA) study: This is a funded Phase II clinical trial (NCT03879577 on Clinicaltrial.gov) in which my role is carrying out pharmacokinetic assessments of Trastuzumab and FEC in the study participants.
 - Gynaecological risk assessment, prevention and treatment (GRASP-T) study: This is a University of Ibadan Research Foundation funded project targeted at employing evidence-based therapies in early detection and management of ovarian cancer in Nigerian patients. My role is with respect to pharmacogenomics in treatment regimen for the study participants.

Both studies are ongoing with simultaneous patient recruitment and study drug administration.

(c) Project, Dissertation and Thesis
Project

- **Odunsi, O.A.** (1999). Physicochemical properties of 4-carboxyl-2, 6-dinitrobenzene azo-1-(naphtha-2-ol). B. Pharm. Project, University of Ibadan.
- **Kotila, O.A.** (2006). Design, synthesis and spectroscopic analysis of AZ-NPA01 as a new chromophoric labelling reagent. M.Sc. Project, University of Ibadan.

Thesis

- **Kotila, O.A.** (2018). *N-Acetyltransferase II Enzyme Genotype-Phenotype Analyses and Association with Sulphonamide Hypersensitivity in HIV-Negative and HIV-Positive Individuals*. Ph.D. Thesis, University of Ibadan

X. Publications

Articles that have already appeared in Learned Journals:

1. Babalola C. P., **Kotila O.**, Samuel B. B., Adetunji O., Gbotosho G. O., Moody J. O., Adeyemi A. M., Adegbola O., Akinyele G., Itiola O. A., Fortunak, J (2024). Building capacity for drug development process in Africa – A workable model. *Pharmacy Education*, 24(1), p. 1–12. <https://doi.org/10.46542/pe.2024.241.112>
2. Babalola C.P., **Kotila O.**, Iwuchukwu O.F. The expanding role of gene-based prescribing for phase II drug-metabolizing enzymes (2023). *American Journal of Pharmacotherapy and Pharmaceutical Sciences* 2023;024. https://doi.org/10.25259/AJPPS_2023_024
3. Coker M.O., **Kotila O.A.**, Adigun T.O., Lawal, T.V., Fagbamigbe, A.F., Makolo, A.U., Salawu, M.M., Ajayi, D.T., Oluniyi, P.E., Oguzie, J.U., Happi, A.N., Hoen, A.G., Babalola, C.P., Ajayi, I.O. (2023). Data science training needs in sub-Saharan Africa: Implications for biomedical research and therapeutics capacity [version 1; peer review: 1 approved]. *Open Res Africa* 2023, 6:21 (<https://doi.org/10.12688/openresafrika.14109.1>)
4. **Kotila O.A**, Ajayi D., Masimerembwa C., Thelingwani R., Odetunde A, Falusi A.G., Babalola C.P. (2023). Non-compartmental and Population Pharmacokinetic Analysis of Dapsone in Healthy Nigerians: A Pilot Study. *British Journal of Clinical Pharmacology* <https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp.15862>
5. Bright B., Sobande Patrick., Alonge Temitope., Babalola C.P., Musa-Olomu A.A., Ali W., **Kotila O.**, Fajimi N., Itodo E.S., Falayi S., Ajayi D., Olatunji A., Adesope T., Ojebunu F., Ologunagba

- M., Aduh , Rotinwa R., Odunfa G., Chukwurah A., Adeyemi S. (2022). Telling the COVID-19 Story – An Overview of Our COVID-19 Study Protocols and Research at Livewell Initiative LWI and Global Public Health University GPHU. *European Journal of Clinical and Biomedical Sciences*, 8(4), 62-70. <https://doi.org/10.11648/j.ejcb.20220804.12>
6. Nwogu, J.N., Ngene, S.O., Babalola, C.P. Olagunju A., Owen A., Khoo, S.H., **Kotila O.A.**, Berzins B., Okochi, H., Tallerico, R., Ghandi, M., Taiwo, B. (2022). Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria. *AIDS Research and Therapy* Vol. 19: 35 <https://doi.org/10.1186/s12981-022-00462-3>
 7. Adejumo P.O, Oluwasanu M.M, Atara N., Awolude O., **Kotila O.A.**, Aniagwu T., Brown B., Dzekem B.S., Duncan S., Tito-Ilori M., Ajani O., Lee S.M, Babalola C.P, Ojengbede O, Huo D., Hammad N and Olopade O. (2022). Oncology Training Needs Assessment Among Healthcare Professionals In Nigeria. *JCO Global Oncology* 8 (2022) e2200017 <https://doi.org/10.1200/GO.22.00017>
 8. Olateju O.A., Babalola C.P., Olubiyi O.O., **Kotila O.A.**, Kwasi D.A., Oaikhen A.O., Okeke I.N. (2021). Quinoline Antimalarials Increase the Antibacterial Activity of Ampicillin. *Frontiers in Microbiology*. <https://doi.org/10.3389/fmicb.2021.556550>
 9. Arinola G.O., Awolude O.A., Ntekim A., Aniagwu T.I.G., Balogun W.O., **Kotila O.A.**, Oluwasanu M., Adejumo P.O., Babalola C.P., Ifechukwude O.M., Oyedele O.M., Olopade O.I., Olopade C.O., Ojengbede O. (2020) Ethics and Responsible Conduct of Research: Workshop Report. *African Journal of Biomedical Research* Vol. 23. SE2: 3-5
 10. Atara, N., Ibraheem, A., Sofoluwe, A.A., Adepoju, T., Oluwasanu, M., Aniagwu, T., Awolude, O., Balogun, W., **Kotila, O.**, Adejumo, P., Babalola, C.P., Arinola, G., Ojengbede, O., Olopade, C.O. and Olopade, O.I. (2020). Implementing Oncology Clinical Trials in Nigeria: A Model for Capacity Building. *BMC Health Services Research* Vol. 20: 713. <https://doi.org/10.1186/s12913-020-05561-3>.
 11. Atara, N.I., Ibraheem, A., Sofoluwe, A.A., **Kotila, O.A.**, Babalola, C.P., Karrison, T. and Olopade, C.O. (2020). ARETTA : Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol. *JCO Global Oncology* Vol. 6. No. 6: 983–90. <https://doi.org/10.1200/GO.20.00043>.
 12. Oluwasanu, M.M., Atara, N., Balogun, W., Awolude, O., **Kotila, O.**, Aniagwu, T., Adejumo, P., Oyedele, O.O., Ogun, M., Arinola, G., Babalola, C.P., Olopade, C.O., Olopade, O.I. and Ojengbede, O. (2019) Causes and Remedies for Low Research Productivity Among Postgraduate Scholars and Early Career Researchers on Non-communicable Diseases in Nigeria. *BMC Research Notes* Vol. 12: 403 <https://doi.org/10.1186/s13104-019-4458-y>
 13. Odeku, O.A., Adisa, R., Adetunji, O.A., Durowaiye, M.A. and **Kotila, O.A.** (2019). Towards the Development of Blueprint for Health Security in Nigeria by 2050: A Review of Drug Development, Supply of Quality Medicines and Treatment Issues. *African Journal of Medicine and Medical Sciences* Vol. 48. Supplement: 185-193.
 14. **Kotila, O.A.**, Fawole, O., Olopade, O.I., Ayede, A.I., Falusi, A.G. and Babalola, C.P. (2019) N-acetyltransferase II Enzyme Genotype-Phenotype Discordances in both HIV-negative and HIV-positive Nigerians. *Pharmacogenetics and Genomics* Vol. 29. No 5: 106-113. <https://doi.org/10.1097/FPC.0000000000000373>.
 15. Nwogu, J.N., **Kotila, O.A.**, Obaro, M. and Babalola, C.P. (2018) Effects of Antacids on the Pharmacokinetics of Lumefantrine in Healthy Volunteers: A Pilot Study. *African Journal of Medicine and Medical Sciences* Vol. 47: 161-169.
 16. Adegoke, A.O., Babalola, C.P., **Kotila, O.A.** and Obuebhor, O. (2017). Simultaneous Spectrophotometric Determination of Trimethoprim and Sulphamethoxazole following Charge-transfer Complexation with Chloranilic acid. *Arabian Journal of Chemistry* Vol. 10. Supplement 2: S3848-3860. <https://doi.org/10.1016/j.arabjc.2014.05.022>.
 17. Akpan, M.R., **Kotila, O.A.**, Akpa, O.M., Fawole, O., Falusi, A.G. and Babalola, C.P. (2015). Self-reported Sulphonamide Hypersensitivity Reactions in Adults Living in Ibadan, Nigeria: A Cross-sectional Community-based Study. *Nigerian Medical Journal* Vol. 56. No. 6: 404-410. <https://doi.org/10.4103/0300-1652.171611>; PMID: 26903698.

18. Babalola, C.P., Oluwalana, I., **Kotila, O.A.**, Adegoke, O.A., Kolade, Y.T. and Ameh, S.J. (2014). A Novel Derivatization Ultraviolet Spectrophotometric Method for the Determination of Dihydroartemisinin using p-Nitroaniline. *Tropical Journal of Pharmaceutical Research* Vol. 13. No.1: 127-133. <https://doi.org/10.4314/tjpr.v13i1.18>.
19. Babalola, C.P., Kolade, Y.T., Adeyemo, M.A., **Kotila, O.A.**, Ameh, S.J., Adelakun, T.A., Adewuyi, S., Kwasi, G.N. and Scriba, G.K. (2014): Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine. *Global Journal of Medical Research: B Pharma, Drug Discovery, Toxicology and Medicine*. Vol. 14. No. 1: 4-10.
20. **Kotila, O.A.**, Olaniyi, O., Adegoke, O.A. and Babalola C.P. (2013): Experimental Determination of the Physicochemical Properties of Lumefantrine. *African Journal of Medicine and Medical Sciences* Vol. 42. No.3: 209-214. PMID: 24579381.
21. Babalola, C.P., Kanu, D.N., Okafor, G.O., Wumi, A., Ajayi, O., **Kotila, O.A.** and Farombi, E.O. (2013): Toxicological Effect of Sub-therapeutic, Therapeutic and Overdose Regimens of Halofantrine Hydrochloride on Male Albino Rats. *Pharmacologia* Vol. 4: 180-185. <https://doi.org/10.5567/pharmacologia.2013.180.185>
22. Babalola, C.P., Ajayi, O., **Kotila, O.A.** and Ameh, S. (2011). In-Vitro Interaction Studies of Lumefantrine with Antacids. *International Journal of Comprehensive Pharmacy (IJCP)* Vol. 3. No. 1: 1-4.
23. Babalola, C.P., **Kotila, O.A.**, Dixon, P.A.F. and Oyewo, A.E. (2011). Disposition of Quinine and its Major Metabolite, 3-hydroxyquinine in Patients with Liver Disease. *Research in Pharmaceutical Biotechnology* Vol. 3. No.3: 25-29. <https://doi.org/10.5897/RPB.9000008>.
24. Babalola, C.P., Awolaye, S.A., Akinyemi, J.O. and **Kotila O.A.** (2011). Evaluation of Prescription Pattern in Southwest Nigeria. *Journal of Public Health and Epidemiology* Vol. 3. No. 3: 94-98. <https://doi.org/10.5897/JPHE.9000052>
25. Adegoke, O.A., Babalola, C.P., Isaac, P.O.K. and **Kotila, O.A.** (2011). Spectrophotometric Studies of the Charge-transfer Complexation between Lumefantrine and Chloranilic acid in Acetonitrile. *Acta Pharmaceutica Scientia* Vol. 53. No. 1: 135-149.
26. Babalola, C.P., Olori, E.O., **Kotila, O.A.**, Falade, O., Kolade, Y.T. and Sylva, B.O. (2009). Effect of Artesunate on the Urinary Excretion of Cloxacillin in Healthy Subjects. *Nigerian Journal of Pharmaceutical Research* Vol. 7. No. 1: 29-36.

XI. Major Conferences Attended with Papers Read (in the last 5 years)

- a) **March 2022.** 3rd edition of the World Conference on Pharmacometrics (WCoP), 29 March - 1 April 2022, Cape Town, South Africa.
Paper presented: **Kotila O.A**, Ajayi D, Masimerembwa C, Thelingwani R, Odetunde A, Falusi A.G., Babalola C.P. Population Pharmacokinetics of Dapsone in Healthy Volunteers in Nigeria: A Pilot Study. Abstract No. 125 (<https://wcop2022.org/2022/02/22/population-pharmacokinetics-of-dapsone-in-healthy-volunteers-in-nigeria-a-pilot-study/>, <https://doi.org/10.1002/psp4.12497>)
- b) **Apr., 2021.** AORTIC Education & Training Symposium
Paper presented: **Kotila, O.A.** Ending the Neglect of Oncology Pharmacy Training in Africa
- c) **Aug., 2020.** 18th Scientific Conference of the Nigerian Association of Pharmacists in Academia (NAPA), 24-26 Aug., University of Nsukka, Nsukka, Nigeria.
Paper presented: **Kotila O.A.**, Akin-Ojo O.D., Adegbola O., Babalola C.P. High-Performance liquid chromatographic method for quantitative estimation of Dolutegravir in bulk drug and pharmaceutical dosage form. Abstract No. 198
- d) **Aug., 2020.** 18th Scientific Conference of the Nigerian Association of Pharmacists in Academia (NAPA), 24-26 Aug., University of Nsukka, Nsukka, Nigeria.
Paper presented: Olajide B.O, Adegbola O.J, **Kotila O.A**, C.P. Babalola1 C.P. Formulation, UV-visible spectrophotometric analysis and stability studies of artemether-lumefantrine suppositories. Abstract No. 197
- e) **Mar., 2019.** Biomedical Science Conference 2019: Genomics of Human Health, organized by Association of Medical Laboratory Scientists of Nigeria (Osun State branch).
Paper presented: Genomics of Infectious Diseases.

- f) **Oct., 2018.** Fogarty International Centre (FIC) Global Network of Grant Holders and their Grantees Focused on Non-communicable Diseases (NCDs), held at Neuroscience Center, 9001 Executive Boulevard, Rockville, MD 20852, USA
Poster presented: N-acetyltransferase II Discordant Genotype-Phenotype Relationship in Nigerians.
- g) **Sept., 2018.** Joint 11th Conference of African Society of Human Genetics & 12th H3Africa Consortium Meeting, 16-23 September 2018 - Kigali Convention Centre.
Paper presented: **Kotila, O.A.**, Fawole, O., Olopade, O.I., Ayede, A.I., Falusi, A.G. and Babalola, C.P. N-acetyltransferase II discordant genotype-phenotype relationship in HIV-positive and HIV-negative Nigerians. (**Won Best Oral Presentation**).
- h) **Nov., 2017.** AORTIC Conference 2017, Kigali, Rwanda, 7-10 November 2017, Abstract No. 274
Paper presented: **Kotila, O.A.**, Chiudo, E.G. and Babalola, C.P. Pharmaceutical non-equivalence of cyclophosphamide generic brands in southwest Nigeria – a lurking danger.
(<http://aorticconference.org/wp-content/uploads/2017/10/2017-AORTIC-Abstracts.pdf>).

XII.

Ten Best Publications that Reflect the Totality of my Contributions to Scholarship

- a) Babalola, C.P., Awolaye, S.A., Akinyemi, J.O. and **Kotila O.A.** (2011). Evaluation of Prescription Pattern in Southwest Nigeria. *Journal of Public Health and Epidemiology* Vol. 3. No. 3: 94-98. <https://doi.org/10.5897/JPHE.9000052>
- b) **Kotila, O.A.**, Fawole, O., Olopade, O.I., Ayede, A.I., Falusi, A.G. and Babalola, C.P. (2019) N-acetyltransferase II Enzyme Genotype-Phenotype Discordances in both HIV-negative and HIV-positive Nigerians. *Pharmacogenetics and Genomics* Vol. 29. No 5: 106-113. <https://doi.org/10.1097/FPC.0000000000000373>
- c) Akpan, M.R., **Kotila, O.A.**, Akpa, O.M., Fawole, O., Falusi, A.G. and Babalola, C.P. (2015). Self-reported Sulphonamide Hypersensitivity Reactions in Adults Living in Ibadan, Nigeria: A Cross-sectional Community-based Study. *Nigerian Medical Journal* Vol. 56. No. 6: 404-410. <https://doi.org/10.4103/0300-1652.171611>; PMID: PMC4743290; PMID: 26903698.
- d) Adegoke, A.O., Babalola, C.P., **Kotila, O.A.** and Obuebhor, O. (2017). Simultaneous Spectrophotometric Determination of Trimethoprim and Sulphamethoxazole following Charge-transfer Complexation with Chloranilic acid. *Arabian Journal of Chemistry* Vol. 10. Supplement 2: S3848-3860. <https://doi.org/10.1016/j.arabjc.2014.05.022>.
- e) **Kotila, O.A.**, Olaniyi, O., Adegoke, O.A. and Babalola C.P. (2013): Experimental Determination of the Physicochemical Properties of Lumefantrine. *African Journal of Medicine and Medical Sciences* Vol. 42. No.3: 209-214. PMID: 24579381.
- f) Adegoke, O.A., Babalola, C.P., Isaac, P.O.K. and **Kotila, O.A.** (2011). Spectrophotometric Studies of the Charge-transfer Complexation between Lumenfantrine and Chloranilic acid in Acetonitrile. *Acta Pharmaceutica Scientia* Vol. 53. No. 1: 135-149.
- g) Babalola, C.P., Oluwalana, I., **Kotila, O.A.**, Adegoke, O.A., Kolade, Y.T. and Ameh, S.J. (2014). A Novel Derivatization Ultraviolet Spectrophotometric Method for the Determination of Dihydroartemisinin using p-Nitroaniline. *Tropical Journal of Pharmaceutical Research* Vol. 13. No.1: 127-133. <https://doi.org/10.4314/tjpr.v13i1.18>.
- h) Babalola, C.P., **Kotila, O.A.**, Dixon, P.A.F. and Oyewo, A.E. (2011). Disposition of Quinine and its Major Metabolite, 3-hydroxyquinine in Patients with Liver Disease. *Research in Pharmaceutical Biotechnology* Vol. 3. No.3: 25-29. <https://doi.org/10.5897/RPB.9000008>.
- i) Atara, N.I., Ibraheem, A., Sofoluwe, A.A., **Kotila, O.A.**, Babalola, C.P., Karrison, T. and Olopade, C.O. (2020). ARETTA : Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women with HER2-Positive Breast Cancer: A Study Protocol. *JCO Global Oncology* Vol. 6. No. 6: 983–90. <https://doi.org/10.1200/GO.20.00043>.
- j) Atara, N., Ibraheem, A., Sofoluwe, A.A., Adepoju, T., Oluwasanu, M., Aniagwu, T., Awolude, O., Balogun, W., **Kotila, O.**, Adejumo, P., Babalola, C.P., Arinola, G., Ojengbede, O., Olopade, C.O. and Olopade, O.I. (2020). Implementing Oncology Clinical

Referees

1. Professor Chinedum Peace Babalola (B.Pharm., FAS., FAAS)
Vice Chancellor,
Chrisland University
No.5 Ajebo Road,
Abeokuta, Ogun State
peacebab@gmail.com; vc@chrislanduniversity.edu.ng
Telephone.: +234-813-300-4582, +234-805-522-4989
2. Dr. Ntekim Atara (FWACS, FMCR)
Department of Radiation Oncology
College of Medicine
University of Ibadan
Email: kimata2000@hotmail.com
Phone: +2348023059292
3. Professor Sunday Olakunle Idowu
Dean, Faculty of Pharmacy
University of Ibadan
olakunleid@gmail.com
+2348058427072

Online bibliographhy

<https://scholar.google.com/citations?user=gEURAxAAAAJ>
<https://www.scopus.com/authid/detail.uri?authorId=44861333400>
ORCID ID 0000-0002-0674-9085



OLAYINKA A. KOTILA (B.Pharm., Ph.D)